Bronchiolitis Obliterans Syndrome (BOS) Recruiting Phase 2 Trials for Ruxolitinib (DB08877)

Also known as: Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans / Obliterative Bronchiolitis / Bronchiolitis Obliterans Syndrome / Obliterating fibrous bronchiolitis (disorder) / Bronchiolitis fibrosa obliterans (disorder) / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04908735Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantTreatment